The premium-priced therapies used to treat ovarian cancer, such as Avastin (Roche/Genentech) and the PARP inhibitors Lynparza (AstraZeneca/Merck & Co), Rubraca (Clovis Oncology), and Zejula (GlaxoSmithKline/Tesaro), result in a significant financial burden for payers. These costs are likely to increase with the expected label expansions of current therapies to new patient populations and the anticipated approval of AstraZeneca’s Imfinzi for newly diagnosed advanced ovarian cancer. As the number of high-priced therapies increases, understanding the market access drivers that are important to payers and oncologists will be essential to maximizing these therapies’ uptake.
How are Avastin and the PARP inhibitors positioned in the treatment algorithm? How have PARP inhibitors been adopted into physician prescribing patterns?
What is the formulary coverage of key brands for ovarian cancer, and what types of cost control have MCOs enacted?
What role does value assessment play in MCOs’ review of ovarian cancer drugs? Which types of information do MCOs use in their assessment?
What are physicians’ views on the key emerging therapies for ovarian cancer? What factors will most influence MCO coverage of an early-line PARP inhibitor-based therapy?
Survey of 100 U.S. medical oncologists.
Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).
KEY DRUGS COVERED
Avastin, Lynparza, Rubraca, Zejula, Imfinzi
Reimbursement and contracting.
Access and prescribing.
Opportunities and challenges for emerging therapies.
U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.
Access & Reimbursement Ovarian Cancer US April 2019
Carolina do Pazo, M.Sc.
Carolina do Pazo, M.Sc., is a senior analyst on the Oncology team at Clarivate. She has authored content on breast cancer, SCCHN, ovarian cancer, and prostate cancer. Previously, she was a research scientist at the Institut Pasteur de Montevideo, where she analyzed the aging process of yeast cells, and she was part of a project between Indiana University and the Universidad ORT that analyzed the production of nanohybrids for drug delivery system applications. As a Chevening Scholar, Ms. Do Pazo completed an M.Sc. in biotechnology, bioprocessing, and business management with distinction at the University of Warwick. She also earned her first-class M.Eng. in biotechnology from the Universidad ORT.
Chris Lewis is a primary research manager at Clarivate. She is responsible for the coordination, content review, and content generation of U.S. Access & Reimbursement reports, including authoring select A&R reports on managed care trends. Before this position, Ms. Lewis was a senior analyst at HealthLeaders-InterStudy. She analyzed the managed care markets in California, New York, and Pennsylvania. She also launched and authored the Pharmacy Benefit Manager profile series. She received her bachelor’s degree from California State University in Sacramento.